Cite
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).
MLA
McCartney, Amelia, et al. “Prognostic Role of Serum Thymidine Kinase 1 Activity in Patients with Hormone Receptor–positive Metastatic Breast Cancer: Analysis of the Randomised Phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).” European Journal of Cancer, vol. 114, June 2019, pp. 55–66. EBSCOhost, https://doi.org/10.1016/j.ejca.2019.04.002.
APA
McCartney, A., Biagioni, C., Schiavon, G., Bergqvist, M., Mattsson, K., Migliaccio, I., Benelli, M., Romagnoli, D., Bonechi, M., Boccalini, G., Pestrin, M., Galardi, F., De Luca, F., Biganzoli, L., Piccart, M., Gradishar, W. J., Chia, S., Di Leo, A., & Malorni, L. (2019). Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor–positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT). European Journal of Cancer, 114, 55–66. https://doi.org/10.1016/j.ejca.2019.04.002
Chicago
McCartney, Amelia, Chiara Biagioni, Gaia Schiavon, Mattias Bergqvist, Karin Mattsson, Ilenia Migliaccio, Matteo Benelli, et al. 2019. “Prognostic Role of Serum Thymidine Kinase 1 Activity in Patients with Hormone Receptor–positive Metastatic Breast Cancer: Analysis of the Randomised Phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT).” European Journal of Cancer 114 (June): 55–66. doi:10.1016/j.ejca.2019.04.002.